-1.png?width=140&height=140&name=Untitled%20design%20(8)-1.png)
Devyser announces study publication demonstrating dd-cfDNA detection in dual donor kidney transplant patients
Devyser Diagnostics AB announces today an article titled “Detection of donor-derived cell-free DNA...
The laboratory
At our state-of the art clinical laboratory, precision, and accuracy is our primary focus. With a team of experienced professionals and cutting-edge technology, we are committed to delivering results you can trust.
Our laboratory is situated in Atlanta, a significant hub for the pharmaceutical and diagnostic industry. The recently acquired facilities are in proximity to the largest airport in the United States, the Atlanta airport, facilitating expedited transportation of blood samples.
“Welcome to our modern US-based clinical laboratory. Our ambition is to provide accurate and reliable results to support the healthcare needs of our communities. Let's work together to improve patient outcomes and lead the way in laboratory excellence.”
- Kelly VanBemmel, Laboratory Operations Supervisor, North America
News | October 29, 2024
Devyser seeks to secure FDA approval for NGS test for kidney transplant monitoringNews | October 28, 2024
Devyser Compact achieves Class III approval in China
Devyser Accept cfDNA demonstrates high performance in newly published peer-reviewed article
Devyser’s NGS products for monitoring of kidney and stem cell transplant patients receive IVDR approvals
Devyser’s novel test for detecting donor-derived cell-free DNA in blood samples from...
Early detection of relapse and early therapeutic intervention: The benefits of Devyser NGS method for chimerism analysis
A better patient care is the final objective for Dr. Helena Devos and the team at Sint Jan’s...